
|Articles|November 15, 2002
Separate and combined drug therapy both work to lower IOP
Los Angeles-A randomized, controlled trial comparing the combination therapy dorzolamide-timolol (Cosopt, Merck) with concomitant administration of 2% dorzolamide (Trusopt, Merck) and 0.5% timolol showed that the IOP lowering is equally effective if the drugs are given either in combination or individually.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves Rayner’s RayOne EMV Toric intraocular lens
2
Avisi Technologies’ investigational device exemption for VisiPlate approved by FDA
3
Ophthalmic innovation by the decades: The 1980s and 1990s
4
NeuroOp Guru: When proptosis isn’t thyroid eye disease
5